|Bid||0.0000 x 1100|
|Ask||0.0000 x 800|
|Day's Range||4.6200 - 5.0100|
|52 Week Range||3.0200 - 20.9900|
|Beta (5Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.50|
Subscribe to Yahoo Finance Plus to view Fair Value for ABOS
Some of the losses seen by insiders who purchased US$5.7m worth of Acumen Pharmaceuticals, Inc. ( NASDAQ:ABOS ) shares...
Thank you for standing by, and welcome to the Acumen Pharmaceuticals first quarter 2022 update call. Thank you for joining us today to review Acumen's first quarter 2022 update on operational progress and financial results. Before we start, we encourage you to read the operational and financial results press release issued this afternoon, which is accessible on our website in the investors section.
Topline results expected in the first half of 2023 from INTERCEPT-AD, a multi-center, randomized, double-blind, placebo-controlled, single- and multiple-ascending dose Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s diseaseFrontiers in Neuroscience recently published a summary of preclinical evidence supporting the development of ACU193, a monoclonal antibody designed to selectively target toxic soluble amyloid-beta oligomers (AβOs), for the potential treatment of early Alzhe